Vindesine in the treatment of malignant mesothelioma: a phase II study.
Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010496:Pericardium; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010997:Pleural Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D014747:Vinblastine; D014751:Vindesine